We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study.
- Authors
SASTRE, JAVIER; GRµVALOS, CRISTINA; RIVERA, FERNANDO; MASSUTI, BARTOMEU; VALLADARES-AYERBES, MANUEL; MARCUELLO, EUGENIO; MANZANO, JOS L.; BENAVIDES, MANUEL; HIDALGO, MANUEL; DÖAZ-RUBIO, EDUARDO; ARANDA, ENRIQUE
- Abstract
Single-agent cetuximab is safe and active in elderly patients with advanced colorectal cancer (CRC). A cetuximab-capecitabine combination has not previously been tested in elderly patients with advanced CRC. Material and Methods. Sixty-six patients with advanced CRC were treated with cetuximab as a 400 mg/m2 i.v. infusion followed by 250 mg/m2 i.v. weekly plus capecitabine at a dose of 1,250 mg/m2 every 12 hours. After the inclusion of 27 patients, the protocol was amended for safety reasons, reducing the dose of capecitabine to 1,000 mg/m2 every 12 hours. Thirty-nine additional patients were treated with the reduced dose of capecitabine. Results. The overall response rate was 31.8%. KRAS status was determined in 58 patients (88%). Fourteen of 29 patients with wild-type KRAS tumors responded (48.3%; 95% confidence interval [CI], 29.4%-67.5%), compared with six of 29 patients with mutant KRAS tumors (20.7%; 95% CI, 8.0%-39.7%). The median progression-free survival (PFS) interval was 7.1 months. The median PFS interval for patients whose tumors were wild-type KRAS was significantly longer than for those with mutant KRAS tumors (8.4 months versus 6.0 months; p = .024). The high incidence of severe paronychia (29.6%) declined (7.7%) after capecitabine dose adjustment. Conclusions. Cetuximab plus capecitabine at a dose of 1,000 mg/m2 every 12 hours may be an alternative to more aggressive regimens in elderly patients with advanced wild-type KRAS CRC.
- Subjects
ANTINEOPLASTIC agents; COMBINATION drug therapy; COLON tumors; CONFIDENCE intervals; DRUGS; LONGITUDINAL method; HEALTH outcome assessment; PATIENT compliance; RECTUM tumors; RESEARCH funding; SCALES (Weighing instruments); SURVIVAL analysis (Biometry); SAMPLE size (Statistics); RELATIVE medical risk; TREATMENT effectiveness; KAPLAN-Meier estimator; OLD age
- Publication
Oncologist, 2012, Vol 17, Issue 3, p339
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2011-0406